Patent · US Active

RPA optimization

US8569015B2 · kind B2 · utility

5Cited by
6References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 30, 2007
Grant dateOct 29, 2013
Priority date—
Expiry dateAug 12, 2030

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K39/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

An optimized synthetic polynucleotide encoding a Bacillus anthracis protective antigen and an anthrax vaccine based on the encoded protective antigen. Furthermore, heterologous expression in a host Pseudomonas fluorescens bacteria of an optimized polynucleotide sequence encoding a Bacillus anthracis protective antigen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.